All In Biotech

Drug Trial Radar · NCT05526391

A Study of TAK-341 in Treatment of Multiple System Atrophy

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

158

Actual

Start

Nov 16, 2022

Primary completion

Jul 28, 2025

Study completion Jul 28, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Sep 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed. This trial will be conducted in North America, Europe and Asia.

Conditions

  • Multiple System Atrophy

Interventions

  • PlaceboDrug

    TAK-341-matching placebo IV infusion

  • TAK-341Drug

    TAK-341 IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52Time frame: Baseline, Week 52

Locations

41 sites in 10 countries. Site status is shown where the registry gives one.

  • Quest Research Institute - Alcanza - HyperCore

    Farmington Hills, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • NYU Langone Health

    New York, New York

  • Duke University School of Medicine

    Durham, North Carolina

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Inland Northwest Research

    Spokane, Washington

  • Medizinische Universitat Graz

    Graz, Styria, Austria

  • Aarhus Universitetshospital

    Aarhus N, Denmark

  • Bispebjerg Hospital

    København NV, Capital, Denmark

  • Hopitaux de La Timone

    Marseille, Bouches-du-Rhone, France

  • Charite - Universitatsmedizin Berlin

    Berlin, Germany

  • Klinikum Groshadern, LMU

    München, Bavaria, Germany

  • Paracelsus-Elena-Klinik Kassel

    Kassel, Hesse, Germany

  • Medizinische Hochschule Hannover

    Hanover, Lower Saxony, Germany

  • Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital

    Bochum, North Rhine-Westphalia, Germany

  • Deutsches Zentrum fur Neurodegenerative Erkrankung

    Bonn, North Rhine-Westphalia, Germany

  • Universitatsklinikum Munster

    Münster, North Rhine-Westphalia, Germany

  • Universitatsklinikum Carl Gustav Carus an der TU Dresden

    Dresden, Saxony, Germany

  • Universitatsklinikum Leipzig

    Leipzig, Saxony, Germany

  • Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio Ruggi dAragona

    Salerno, Italy

  • IRCCS San Raffaele Roma

    Rome, Lazio, Italy

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta

    Milan, Lombardy, Italy

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, Italy

  • Azienda Ospedale Universita Padova

    Padova, Veneto, Italy

  • Chiba University Hospital

    Chuo-ku, Chiba, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Kyoto University Hospital

    Kyoto, Kyoto, Japan

  • The University of Tokyo Hospital

    Bunkyo-Ku, Tokyo, Japan

  • Medical Hospital of Tokyo Medical and Dental University

    Bunkyo-Ku, Tokyo, Japan

  • National Center of Neurology and Psychiatry

    Kodaira-Shi, Tokyo, Japan

  • Campus Neurologico Senior

    Loures, Lisbon District, Portugal

  • Hospital Pedro Hispano

    Senhora da Hora, Porto District, Portugal

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario de La Princesa

    Madrid, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain

  • Hospital Universitario Cruces

    Barakaldo, Vizcaya, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.